<DOC>
	<DOC>NCT02142868</DOC>
	<brief_summary>To provide access to palbociclib to post-menopausal women with HR-positive, HER2-negative advanced breast cancer who are deemed appropriate for letrozole therapy (Canada: first-line patients only).</brief_summary>
	<brief_title>Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate</brief_title>
	<detailed_description>This study is currently available in Canada only.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal women 18 years of age or above with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease) ERpositive and/or PRpositive tumor based on local laboratory results HER2negative tumor based on local laboratory results Patients must be appropriate candidates for letrozole therapy (Canada: firstline patients only) Patients who have previously participated in a palbociclib trial or who have received prior treatment with any CDK inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Expanded Access</keyword>
	<keyword>Advanced Breast Cancer</keyword>
</DOC>